Clinical Trial Update: DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02) [Phase 2]

View source ↗

Summary

The DESTINY-Gastric02 Phase 2 trial of DS-8201a (trastuzumab deruxtecan) in HER2-positive unresectable or metastatic gastric cancer has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Daiichi Sankyo | Conditions: Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ | Phase 2 | Status: COMPLETED | Results posted: 2022-01-12